کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8612312 | 1567319 | 2018 | 28 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
بیهوشی و پزشکی درد
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
The combination of buparlisib with capecitabine in patients with metastatic breast cancer was generally well-tolerated, with several patients demonstrating prolonged responses. Unexpectedly low rates of PIK3CA mutations (3 of 17) were seen, and only 2 of 7 tumors with subtyping were luminal, making exploration of these putative predictive markers impossible. Further study of the combination is not unreasonable, with expanded pharmacokinetics and sequencing analysis to better elucidate potential drug-drug interactions and more accurate predictive biomarkers of response.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Breast Cancer - Volume 18, Issue 4, August 2018, Pages 289-297
Journal: Clinical Breast Cancer - Volume 18, Issue 4, August 2018, Pages 289-297
نویسندگان
Autumn J. McRee, Paul K. Marcom, Dominic T. Moore, William C. Zamboni, Zachary A. Kornblum, Zhiyuan Hu, Rachel Phipps, Carey K. Anders, Katherine Reeder-Hayes, Lisa A. Carey, Karen E. Weck, Charles M. Perou, E. Claire Dees,